24 February 2025

LiU-researcher Frank Hernandez has received a grant for his research in designing antibiotics that can be administered with precision. It is one of 23 approved grants by The Swedish Research Council (VR) that focuses on antimicrobial resistance.

Frank Hernandez, Baris Borsa, Anna Carolina Lenhart
Frank Hernandez, Baris Borsa, Anna Carolina Lenhart

His project is developing a new class of drugs based on precision medicine principles. These drugs are designed to target specific organs or tissues, enhancing therapeutic efficacy while minimizing side effects.
“The technology can be used to treat localized infections, such as skin and soft tissue infections, osteomyelitis, endocarditis, and pneumonia, says Frank Hernandez”

The goal is to complete the preclinical phase for an experimental antibiotic and initiate first-in-human studies to bring this innovative technology closer to clinical use.
"This project represents the second phase of our TOUCAN platform development."

TOUCAN Technology, a company co-founded by Frank Hernandez and soon transferred to Theralia AB, integrates conventional drugs with a nano-transport system for targeted delivery. Like a GPS it identifies bacterial infections within the body, delivering treatment with high precision, efficacy, and minimal side effects.
“The nano-transport is a short nucleic acid (e.g., DNA) carrying the drug. It remains inactive in the blood and only activates upon detecting a bacterial infection, releasing the drug to kill bacteria. This makes the drug harmless and safer for other parts of the body. In short, the drug works only where it's needed.”

Although demonstrated in bacterial infections, this approach has potential applications for treating conditions such as cancer and autoimmune diseases.
“The ultimate goal of this project is to begin the validation of TOUCAN technology in human clinical trials through the development of the first targeted antibiotics. Once the pre-clinical phase is completed, we will validate the safety features of the TOUCAN technology in humans, followed by its application in treating infections using this technology”, says Frank Hernandez.


Contact

Latest news from LiU

LiU and Region Östergötland invest in AI and precision health

Linköping University and Region Östergötland announce initiatives in the areas of life science, medtech, innovation and information-driven precision health in a new collaboration agreement.

A man in a lab applies water to the surface of a yellow-green material.

More effective production of “green” hydrogen with new combined material

Hydrogen produced from water is a promising renewable energy source – especially if the hydrogen is produced using sunlight. Now LiU researchers show that a combination of new materials improves the efficiency of the chemical reaction several times.

Demonstration of MR elastography.

Fatty liver – but not liver damage – common in type 2 diabetes

Six out of ten people with type 2 diabetes had fatty liver in a new study. Of these, only a small percentage had developed more severe liver disease. Type 2 diabetes in combination with obesity is linked to a greater risk.